Coya Therapeutics (COYA) Cash from Financing Activities (2022 - 2026)

Coya Therapeutics has reported Cash from Financing Activities for 5 years, with the latest figure at $11.0 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 57356.17% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.4 million (up 111.85% YoY) and the FY2025 annual result came in at $20.4 million, up 27.21% from the prior year.
• Cash from Financing Activities retreated to $11.0 million in Q1 2026 per COYA's latest filing, from $20.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $24.2 million in Q4 2023 and troughed at -$104071.0 in Q4 2022.
• A 5-year average of $6.8 million and a median of $3.2 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities sank 98.46% in 2025, then soared 57356.17% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$104071.0 in 2022, then surged by 23329.1% to $24.2 million in 2023, then tumbled by 59.91% to $9.7 million in 2024, then soared by 109.95% to $20.3 million in 2025, then plunged by 45.97% to $11.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $11.0 million, $20.3 million, and $19137.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.